# Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy

> **NCT06501651** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Sichuan Academy of Medical Sciences** · enrollment: 297 (estimated)

## Conditions studied

- Essential Hypertension
- Type 2 Diabetes
- Nephropathy

## Interventions

- **DRUG:** Sacubitril/Valsartan
- **DRUG:** Valsartan

## Key facts

- **NCT ID:** NCT06501651
- **Lead sponsor:** Sichuan Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2025-04-10
- **Final completion:** 2025-04-10
- **Target enrollment:** 297 (ESTIMATED)
- **Last updated:** 2024-07-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06501651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06501651, "Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06501651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*